Philmans Pharm, Cenedella.de, The German Patient Roundtable

Est. 1977

Study: Oral THC Safe And Effective For Treatment Of Spasticity In Pediatric Patients – Dusseldorf, Germany

http://norml.org/news/2016/09/01/study-oral-thc-safe-and-effective-for-treatment-of-spasticity-in-pediatric-patients 

Thursday, 01 September 2016

Study: Oral THC Safe And Effective For Treatment Of Spasticity In Pediatric PatientsDusseldorf, Germany: The administration of oral, synthetic THC (dronabinol) is safe and effective for the treatment of refractory spasticity in pediatric patients, according to clinical data published online ahead of print in the European Journal of Pediatric Neurology.

Researchers from the University of Dusseldorf in Germany assessed the palliative treatment of dronabinol in 16 adolescent subjects with complex neurological conditions. Subjects received dosing twice daily and the median duration of treatment was 181 days.

Oral THC administration was associated with reduced spasticity in the majority of subjects treated. No serious or enduring side effects were reported. “Our data show evidence that dronabinol can effectively be administered over a longer period of time to … young children … without severe side effects or aggravation of pre-existing concurrent conditions,” authors concluded.

The study is one of the first trials to specifically assess the safety and efficacy of THC in an adolescent patient population.

The US Food and Drug Administration approved the prescription use of oral, synthetic THC as an anti-emetic and as an appetite stimulant in the mid 1980s. A liquid version of dronabinol was FDA approvedfor similar purposes earlier this year.

For more information, please contact Paul Armentano, NORML Deputy Director, at: paul@norml.org. Full text of the study, “Effective treatment of spasticity using dronabinol in pediatric palliative care,” appears in the European Journal of Pediatric Neurology.

Author: Cenedella.de

Over the last 4 decades I have been involved in the fight for patient rights in America, and now here in Germany. During my career I have served as a Board of Director for the World Trade Center San Diego and as a Lead Consultant for Deutsche Telekom's Executive Board, Co-Founded the San Diego Software Council and the Dayton Human Trafficking Accords and was Director of LawInfo's Lead Council Program. Previously I was a C-Level Business Development Executive in the technology sector, but also involved with the cannabis industry since 1977. More recently I have been fulltime in the legal medical marijuana industry here in Europe, helping international companies navigate the biggest potential market in the world. This website is light on details due to confidentiality issues with clients but be rest assured I am knowledgeable, professional and with street cred in the industry that can immediately assist your growth in some way. Consulting Services: Sales and Business Development Assist with Strategic Direction Professionally represent your firm Special Projects management Licensing and compliance Sales and Distribution networks Qualify potential partners I am your resource on the ground in Europe, contact me directly to schedule an initial discussion on the German Cannabis-as-Medicine market. Thank you, Philip J. Cenedella IV Call +1.888.206.3264 USA +49.0.151.720.17652 GERMANY Skype: philip.j.cenedella eMail: phil@cenedella.de LinkedIN: https://www.linkedin.com/in/cenedellade/

Comments are closed.